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Obesity is a major public health issue worldwide. Current pharmacological treatments are largely unsuccessful. Determining the
complex pathways that regulate food intake may aid the development of new treatments. The hypothalamic-pituitary-thyroid
(HPT) axis has well-known eﬀects on energy expenditure, but its role in the regulation of food intake is less well characterised.
Evidence suggests that the HPT axis can directly inﬂuence food intake. Thyroid dysfunction can have clinically signiﬁcant
consequences on appetite and body weight. Classically, these eﬀects were thought to be mediated by the peripheral eﬀects of
thyroid hormone. However, more recently, local regulation of thyroid hormone in the central nervous system (CNS) is thought
to play an important role in physiologically regulating appetite. This paper focuses on the role of the HPT and thyroid hormone
in appetite and provides evidence for potential new targets for anti-obesity agents.
1.Introduction
Obesity, its complications, and the associated mortality are
major public health issues worldwide. The major central
nervous system (CNS) areas important in the regulation
of appetite are the hypothalamus and brainstem. The
hypothalamus interprets and integrates aﬀerent signals from
the periphery and brainstem to modulate eﬀerent signals
that regulate food intake and energy expenditure. Neural
and hormonalperipheral signals communicate information
including acute nutritional states and energy stores. The
hypothalamus is subdivided into a number of interconnect-
ing nuclei, including the paraventricular nucleus (PVN),
the ventromedial nucleus (VMN), and the arcuate nucleus
(ARC),whichareparticularlyimportantinregulatingenergy
homeostasis. The ARC is located near the median eminence,
where the blood-brain barrier is incomplete, and is thus
well positioned to respond to circulating factors involved in
appetite and food intake [1]. Recent evidence suggests that
thyroid hormones may access the ARC and other regions of
the hypothalamus to regulate appetite (Figure 1).
It is well established that the hypothalamic-pituitary-
thyroid (HPT) axis regulates body weight. Thyroid hor-
mones are known to eﬀect metabolic rate. Thyroid dys-
function can have clinically signiﬁcant consequences on
appetite and body weight. Hypothyroidism classically causes
reduced basal energy expenditure [2]w i t hw e i g h tg a i n
[3, 4]. Conversely, hyperthyroidism increases energy expen-
diture and reduces body weight [5–7]. Traditionally, it has
been assumed that it is this reduced body weight that
drives the hyperphagia that can be a presenting feature
in hyperthyroidism. However, recent evidence suggests that
the HPT axis may play a direct role in the hypothalamic
regulation of appetite, independent of eﬀects on energy
expenditure. Classically, hypothalamic thyrotropin-releasing
hormone (TRH) stimulates thyroid-stimulating hormone
(TSH) release from the anterior pituitary gland, which
then stimulates the release of both thyroid hormones, tri-
iodothyronine (T3) and thyroxine (T4). Reports suggest that
all of these signalling molecules can directly inﬂuence food
intake [8–11]. Improved understanding of the role of the
HPT axis and thyroid hormone in appetite may identify new
targets for antiobesity agents.
2. Effects of Thyroid Hormones on
FoodIntake(Table 1)
There are well-characterised eﬀects of fasting on hypotha-
lamic TRH expression. This is primarily thought to down-
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Figure 1: Schematic diagram of central appetite regulation. T3
can access the hypothalamus and brainstem via the incomplete
blood brain barrier. PVN: paraventricular nucleus; ARC: arcuate
nucleus; VMN: ventromedial nucleus; BBB: blood-brain barrier;
T3: triiodothyronine; POMC: Pro-opiomelanocortin; NPY: neu-
ropeptide Y; AgRP: agouti-related protein; BDNF: brain-derived
neurotrophic factor; HPT: hypothalamic-pituitary thyroid; SNS:
sympathetic nervous system.
thus reducing food intake. However, TRH has been reported
to have direct anorectic eﬀects, suggesting it may regulate
food intake independent of eﬀects on the HPT axis. In
rodents, central administration of TRH reduces food intake
[8, 12, 13]; similar eﬀects on food intake are seen following
peripheral administration [14].
TSH has also been shown to reduce food intake when
injected centrally into rats [8]. There is evidence that TSH
from the pars tuberalis is involved in the photoperiodic
response in birds and rodents, and it is thus possible that
TSH is involved with the seasonal alterations in food intake
and body weight that occur in some species [15–17].
The hyperphagia associated with hyperthyroidism may
be a result of thyroid hormones acting directly on CNS
appetite circuits. T3 directly stimulates food intake at the
level of the hypothalamus. In rodent models, peripheral and
central hypothalamic administration of T3 increases food
intake [9–11].
There are several mechanisms postulated to mediate
the orexigenic eﬀects of thyroid hormones. The ARC
contains two distinct energy homeostasis-regulating neu-
ronal populations. One subpopulation expresses the pro-
opiomelanocortin(POMC)genewhichcodesfortheanorec-
tic neuropeptide alpha-melanocyte-stimulating hormone
(α-MSH). The other expresses the orexigenic factors neu-
ropeptide Y (NPY) and agouti-related protein (AgRP). It has
been reported that peripheral administration of T3 increases
hypothalamic NPY mRNA and that intracerebroventricular
(ICV)administrationofaNPYY1receptorantagonistblunts
T3 induced hyperphagia, suggesting that T3 may increase
appetite via NPY [10]. T3 administration was also reported
toalso reduce hypothalamic POMC expression [10]. Another
study did not detect changes in hypothalamic neuropeptide
Table 1: Eﬀect of TRH, TSH, and T3 on food intake. Central
administration of TRH and TSH in rodents causes a reduction
in food intake [8, 12, 13]; similar eﬀects on food intake are
seen following peripheral administration of TRH [14]. Central
and peripheral administration of T3 increases food intake [9–11].
TRH: thyrotropin releasing hormone; TSH: thyroid-stimulating
hormone; T3: triiodothyronine.




expression in response to peripheral administration of T3
thoughthismayreﬂectthediﬀerentdosesofT3administered
[9].
However, the eﬀects of thyroid hormones on food
intake may not be mediated directly by the ARC. Direct
administration of T3 into the VMN but not the ARC
increases food intake in rats [9]. As appetite regulating
circuits in the ARC are known to be altered by changes in the
HPT, there may be an indirect eﬀectof the ARC via the VMN
allowing intra-VMN T3 to increase food intake. In keeping
with this, there are excitatory inputs into POMC neurons
that originate in the VMN [18].
The eﬀects of T3 in the VMN may be mediated by
glutamate [19] and/or brain-derived neurotrophic factor
(BDNF) neurons [20]. The VMN is likely to be the source of
glutamatergic neurons that modulate ARC POMC neurons.
IthasnotbeeninvestigatedwhetherT3,forexample,inhibits
glutamatesynthesisand/orreleasetodisruptexcitatoryinput
into POMC neurons. However, it is interesting to note that
there is evidence from other tissues that HPT activity can
regulate glutamatergic neuronal machinery. For example,
hypothyroidism increases expression of the vesicular gluta-
mate transporter vGLUT-2 in the anterior pituitary [21].
BDNF is a protein belonging to the neurotrophin family
of growth factors, which regulate growth, diﬀerentiation
and survival of neurons. BDNF is highly expressed in the
VMN and is reduced by 60% with fasting chronic ICV
administration of BDNF signiﬁcantly reduces food intake in
rats [22]. BDNF is thought to act via the tyrosine kinase
receptor TrkB. In accord with this, rodents with reduced
TrkB expression develop hyperphagia and obesity [23]. In
vitro data suggest that T3 reduces BDNF gene expression
when applied to hypothalamic explants [20]. However,
VMN BDNF may not be physiologically important in the
regulation of food intake. Steroidogenic factor-1 (SF1) is a
transcription factor which is expressed in of the VMN and
which is often used as a molecular marker for the VMN.
Leptin depolarizes and increases the ﬁring rate of VMN SF1
neurons, suggesting they are involved in the regulation of
energy homeostasis. Mice speciﬁcally lacking BDNF in SF1
neurons do not develop the obese phenotype observed in
other BDNF-deﬁcient models, suggesting that VMN BDNF
may not play an important role in food intake [24]. Further
work is required to determine the role of BDNF in mediating












Figure 2: Eﬀect of fasting on the hypothalamo-pituitary-thyroid
axis. PVN: paraventricular nucleus; ARC: arcuate nucleus; TRH:
thyrotropin releasing hormone; TSH: Thyroid-stimulating hor-
mone; T3: triiodothyronine; T4: thyroxine; POMC: Pro-opiome-
lanocortin; NPY: neuropeptide Y; AgRP: agouti-related protein.
Theenzyme5  adenosinemonophosphate-activatedpro-
tein kinase (AMPK) is thought to act as a sensor which
regulates cellular energy homeostasis. AMPK is activated
by phosphorylation, and AMPK activation in the ARC
increases food intake [25]. Peripherally administered T3
increases hypothalamic AMPK phosphorylation, which thus
may mediate the orexigenic eﬀects of T3 [11].
Thyroid hormone derivatives have also been implicated
in the regulation of appetite. G protein-coupled trace
amine-associated receptor 1 (TAAR1) is expressed in the
rat hypothalamus and is associated with the regulation of
energy homeostasis. Thyroid hormone derivative 3-iodoth-
yronamine (T1AM), an endogenous biogenic amine, is a
potent agonist of TAAR1. Rodent studies show that T1AM
signiﬁcantly increases food intake in rats, when adminis-
tered intraperitoneally, ICV, or directly into the ARC [26].
However, the physiological relevance of these eﬀects remains
unknown.
The thyroid hormone receptor (TR) or receptors that
mediate the eﬀects of thyroid hormones on appetite are
unknown. There are two main types of thyroid hormone
receptors—thyroidhormonereceptorα(THRA)andthyroid
hormone receptor β (THRB), each coded by a distinct
gene. These genes are alternately spliced to generate three
major highly homologous nuclear receptor isoforms (TRα1,
TRβ1, and TRβ2) with speciﬁc tissue distributions [27].
The three main isoforms bind T3 with high aﬃnity, and
regulate thyroid hormone-mediated transcription. TRα is
the main isoform regulating T3 activity in the heart, skeletal
muscle, bone and brain; TRβ is the main isoform regulating
T3 activity in the liver. Adipose tissue expresses both TRα
and TRβ.T R β1 is expressed in most tissues, whilst TRβ2
is expressed solely in the hypothalamus, pituitary, cochlea,
and retina [28, 29]. All three isoforms are expressed in the
human hypothalamus in a number of nuclei, including the
infundibular nucleus, the human equivalent of the ARC, and
the supraoptic and paraventricular nuclei.
Although thyroid hormones can directly increase food
intakeinthehypothalamus,selectivelytargetingTRsubtypes
have been shown to have beneﬁcial metabolic eﬀects. Activa-
tion of the TRβ receptor reduces body weight in obese rats
[30], which may be a result of an increase in metabolic rate.
Hence, TRβ agonists have been proposed as treatments for
obesity. Targeting the TR with a TRβ-selective agonist may
determine whether these agents address the metabolic eﬀects
of thyroid hormone, without eﬀects on the TRα-expressing
tissues such as the heart [30]. Peripheral administration of
aT R β-selective agonist to rats during feeding with a high-
fat diet prevents the expected increases in fat mass, glucose
intolerance, and hypertriglyceridaemia [31]. These eﬀects
may reﬂect the increased energy expenditure observed in
rodents treated with a TRβ-selective agonist rather than
the eﬀects of thyroid hormones on appetite [32]. Further
work is required to identify the receptor responsible for the
orexigenic eﬀects of T3 in the hypothalamus.
3. Effects of NutritionalState on
Thyroid Hormones
Reduction in TRH in response to fasting may be important
as TRH is seen to have a direct anorectic eﬀect when injected
into the hypothalamus [13]. It is possible there are distinct
TRH neuronal populations regulating the HPT axis and
regulating appetite.
In periods of limited food availability, there is central
downregulation of the HPT axis. Serum T4 and T3 levels
fall during fasting in humans [33] and rodents [34, 35].
As the majority of T3 in rodents comes from the thyroid
gland, it is thought food deprivation may result in a fall
in the release of T4 and T3. This is likely secondary to a
reduction in hypothalamic TRH expression, an eﬀect that
may be mediated by the adipose hormone leptin (Figure 2).
Leptin is an adipocytokine that circulates in proportion
to white adipose tissue and communicates information
regarding body fat stores to the CNS. Administration of
leptin can reverse starvation induced changes of the HPT
axis [34, 36, 37]. Leptin administration partially prevents
t h er e d u c t i o ni nt o t a lT 4c l e a r l yo b s e r v e di nf a s t e dm i c e
[34]. Humans and mice with mutations of leptin receptor
or leptin itself exhibit central hypothyroidism [38, 39],
which is ameliorated in leptin-deﬁcient humans by the
administration of leptin [40]. Leptin may directly regulate
TRHexpressioninthePVNandmayindirectlyregulateTRH
via eﬀects in the ARC. Leptin increases α-MSH release and
decreasesAgRP release, which results in a downregulation
of TRH expression. There is also emerging evidence of the
existence of a melanocortin-independent pathway by which
leptin can inﬂuence the HPT axis; cotreatment with a potent
melanocortin 4 receptor (MC4R) antagonist diminishes but
d o e sn o tf u l l yb l o c kl e p t i na c t i o ni nr e s t o r i n gt o t a lT 4i na
rodent model [41].
However, the changes in the HPT axis and peripheral
thyroid hormone levels are at odds with the reported eﬀects
of thyroid hormones on appetite. If thyroid hormones
physiologically increase appetite, they would be predicted
















Figure 3: Eﬀect and consequences of fasting on central T3 levels,
mediated by D2 and D3. PVN: paraventricular nucleus; ARC:
arcuate nucleus; VMN: ventromedial nucleus; TRH: thyrotropin
releasing hormone; T4: thyroxine; T3: triiodothyronine; OATP1C1:
Organic anion transporting polypeptide 1c1; MCT8: monocar-
boxylate transporter 8; D2: Deiodinase 2; D3: deiodinase 3; NPY:
Neuropeptide Y; AgRP: agouti-related protein; UCP2: uncoupling
protein 2.
suggests that rather than systemic thyroid hormone levels,
it is local CNS concentrations of thyroid hormones that are
important in the regulation of appetite.
4. CentralChanges inT3 Levels Mediatedby
D2 andD3
A group of enzymes known as the deiodinases (thioredoxin
fold enzymes) regulates the activation and inactivation of
T3 and T4. These enzymes are responsible for regulating
centralthyroid hormone levels. There are three types of
deiodinase,eachwithanactivesitecontainingtheaminoacid
selenocysteine, which is critical for the deiodination reaction
catalysed by these enzymes. Deiodinases act by selectively
removing of iodine from T4 and its derivatives. Iodine may
be removed from the inner (tyrosyl) or outer (phenolic)
ring. Deiodinase 1 (D1) is expressed predominantly in the
liver, kidney, and thyroid in humans and rodents. However,
Deiodinase 2 (D2) and Deiodinase 3 (D3) are highly
expressed within the CNS, with some peripheral expression.
The expression of each enzyme is regulated individually by
thyroid hormone. Within the hypothalamus, expression and
activity of D2 and D3 depend on nutritional circumstances,
leading to tissue speciﬁc changes in hypothalamic T3 avail-
abilitythatmaybeimportantintheregulationoffoodintake
and energy expenditure (Figure 3).
D2 catalyses the conversion of T4 to T3 to generate
intracellular T3 [42]. It is particularly important in the
brain. D2 plays an important part in thyroid hormone-
mediated feedback regulation of TRH production. Dio2
knockout mice have higher levels of serum T4 and TSH;
however, administration of T3, but not T4, suppresses TSH,
suggesting central T4 resistance [43]. Hence the activity of
D2 is crucial in the feedback regulation of TSH secretion.
T3-driven suppression of TRH expression in the PVN
[44] can be prevented by infusion of the D2 inhibitor
iopanoic acid [45]. D2 is not expressed in hypophysiotropic
neurons [46] but is highly expressed in tanycytes [47],
specialised endothelial cells which line the third ventricle.
Tanycytesexpresstwothyroidhormonespeciﬁctransporters:
monocarboxylate transporter 8 (MCT8) and organic anion
transporting polypeptide 1C1 (OATP1C1) in rodent models
[48]. D2 mediates the conversion of T4 to T3 within these
tanycytes, allowing T3 to access the TRH neurons of the
PVN. MCT8 is thought to modulate neuronal uptake of
thyroid hormone in mice [49], ensuring that TRH produc-
tion is regulated by peripheral T4 concentration, under basal
conditions. Expression of Dio2 and D2 activity are increased
in hypothyroidism [50] and fall with the administration of
T4, protecting tissues from the adverse eﬀects of extremes of
thyroid dysfunction [51].
Hypothalamic D2 expression is not just regulated by
thyroid status. In rodents, fasting also increases hypotha-
lamic D2 expression and activity [9, 37], and this eﬀect
is not reversed by systemic administration of T4 [45]. It
can, however, be reversed by leptin administration [37],
suggesting it is more important in energy homeostasis than
the HPT axis. Leptin restores the hypothalamic and pituitary
components of the HPT axis during fasting, but directly
blunts the response of the thyroidgland, resulting in low
plasma T4 and T3 [37]. Hence, normalization of thyroid
hormone may depend on changes in deiodinase activities
and the long-term thyroid stimulation by TSH to oppose
these direct inhibitory eﬀects of leptin on the thyroid.
D2 activity is particularly high in the ARC and median
eminence [52], where it is expressed within astrocytes and
tanycytes. The processes of the D2 containing tanycytes are
in direct contact with NPY/AgRP neurons of the ARC which
also express UCP2 [53]. Uncoupling protein 1 (UCP1) is
thought to be integral to the process of brown-fat-associated
nonshivering thermogenesis, as it dissipates energy in the
form of heat [54]. The role of inner mitochondrial mem-
brane uncoupling protein 2 (UCP2) is less well deﬁned and
tissue speciﬁc, but it is subject to regulation by T3 [55].
T3 is thought to access CNS target neurons via a number
of diﬀerent mechanisms. One is through a direct crossing of
the blood-brain barrier (BBB). Alternatively T3 may cross
the BBB via astrocytes encircling endothelial cells, following
5  deiodination of T4 taken up from the blood. Astrocytes
in the ARC are of particular importance as they express
leptin receptors [56, 57]. Another postulated mechanism
of T3 transport to target neurons is hypothalamic thyroid
hormone uptake from the CSF, with thyroid hormone being
taken up from the CSF in the third ventricle and transported
by tanycytes to neurons in the ARC that project to TRH
cells in the PVN [58]. Upregulation of ARC D2 activity
duringfooddeprivationcausesincreasedlocalbioavailability
of T3 in the ARC, leading to increased UCP2 activity and
mitochondrial proliferation within the NPY/AgRP neurons
[53]. In Dio2 null mice, food deprivation does not result in
the characteristic increase in hypothalamic NPY expression
[53], suggesting that D2-driven T3 production is crucial toJournal of Thyroid Research 5
maintain the normal hypothalamic response to fasting. TSH
fromtheparstuberalisinducesDio2expressioninthemouse
hypothalamusaspartofthephotoperiodicresponse,andthis
may thus increase hypothalamic T3 levels [16]. However, it
is currently unknown whether these changes are responsible
for photoperiodic changes in food intake.
D3 is responsible for the inactivation of T4 to rT3 and
T3 to 3 ,3 -diiodothyronine (T2) by inner-ring deiodination
[59]. D3 preferentially uses T3 as a substrate rather than
T4. D3 is predominantly expressed in the adult CNS [60]
but is also expressed in the placenta, pregnant uterus, and
fetal tissues. D3 mRNA is expressed in the rat hypothalamus
and other CNS regions [61]. In the CNS, D3 activity is
mediated by levels of thyroid hormone, with higher levels
in hyperthyroidism and lower levels in hypothyroidism [61].
Expression of D3 in peripheral tissues is relatively low, but it
can be induced in the liver and skeletal muscle of critically
ill patients and has been postulated to be responsible for the
characteristic changes of reduced levels of TSH and thyroid
hormone seen in the sick euthyroid syndrome [62]. D3 may
also play a role in the regulation of food intake. Hibernating
Siberian hamsters show signiﬁcant changes in food intake
and energy expenditure depending on photoperiod. During
short photoperiod days, which would naturally occur during
winter months they have reduced food intake and body
weightandtheircorebodytemperaturefalls[63].Expression
and activity of hypothalamic D3 is increased in these
animals during the same period, causing a reduction in local
bioavailability of T3. The reductions in food intake and body
weight can be reversed by the implantation of a T3 pellet
into the dorsomedial hypothalamus, suggesting that it may
be the changes in hypothalamic D3 that is responsible for
these eﬀects on energy homeostasis [64].
5. Summary
Local regulation of thyroid hormones in the CNS may physi-
ologically regulate appetite. Switching between the induction
of D2 and D3 expression may ﬁnely control hypothalamic
thyroid hormone concentrations. Further work is now
required in order to characterise the pathways by which
thyroid hormones regulate food intake. Determining the
mechanisms by which thyroid hormones regulate energy
homeostasis may aid the development of therapies for the
management of obesity.
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